NexTel Medical amends JumpstartRx, NuevistraMed deal to buy parent Island 40 Group for $12.75 million
MARIJUANA INC
MARIJUANA INC MAJI | 0.00 |
- NexTel Medical amended its previously disclosed deal to buy Island 40 Group, replacing the earlier plan to acquire JumpstartRx and NuevistraMed.
- The revised transaction brings Island 40’s full subsidiary platform, expanding into health services, pharmaceutical access, lab testing, and institutional partnerships.
- Total consideration is $12.75 million, comprised of $3.5 million cash and $9.25 million preferred stock.
- Island 40’s platform reaches more than 300,000 patients per month through affiliated channels.
- Closing remains subject to customary conditions, including completion of financial review and due diligence.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nextel Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607221216PRIMZONEFULLFEED9766438) on July 22, 2026, and is solely responsible for the information contained therein.
